Clarity in Chemistry
Guided by Tumor Biology
Advancing Next-Generation ADCs to Life-changing Cancer Therapies
About
ClearideBio Therapeutics is a biopharmaceutical company dedicated to catalyzing cutting-edge antibody-drug conjugate (ADC) innovations into life-changing treatments for cancer patients worldwide. Through efficient development and agile partnerships, we aim to deliver more tumor-specific actions with reduced systemic toxicity to unlock durable benefits for patients.
Our Success is defined by the impact we deliver for patients and partners.
Safety-led efficacy
ADCs for clinically meaningful differentiation by truly widening the window between potency and tolerability.
Data-first
Connecting innovation across borders to translate evidence and data into de-risked development decisions and high-confidence execution.
Asset-centric
A rigorous, data-led path from candidate selection to clinical translation-optimized for execution efficiency.
Leadership Team
We are dedicated ADC developers with deep expertise and a track record of value creation. Our team combines complementary strengths and multidimensional translational insight - navigating complexity with precision and advancing programs from innovation to patient impact.
Xiaona Jing
CEO & Co-Founder
Pawel Chrom
CMO & Co-Founder
Daniel Lustenberger
CFO
Partnership
Partnering to Accelerate ADC Innovation
Innovators
Translate early ADC innovations into clinical breakthroughs through our development expertise and global execution pathways.
Investors
Back a de-risked, milestone-driven ADC strategy built to generate decision-grade data, reduce key risks and drive durable value creation.
Partners
Count on us as a focused ADC collaborator-rigorous in science, strong in execution, and aligned on outcomes.
Contact
Our Headquarter
ClearideBio Therapeutics AG
Lichtstrasse 354056 Basel, Switzerland
HongKong Office
ClearideBio Limited
Room 602, 6/F, Kai Yue Commercial Building, No.2C, Argyle Street, Mongkok Kowloon, Hong Kong